By physician referral or invitation only

A Multi-Institution Study of Universal Donor NK Cell Infusions in Combination with Gemcitabine and Docetaxel in Patients with Relapsed or Refractory Pediatric Bone and Soft Tissue Sarcomas: The TiNKS Trial

The purpose of this study is to determine the safety of the addition of universal donor, expanded NK cells to gemcitabine/docetaxel for treatment of relapsed and refractory sarcomas.

Age & Gender

1 years ~ 19 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

Patrick Thompson
Pediatrics - Hematology/Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Bones, Joints, Muscles
Cancer (Pediatric Cancers, Sarcoma (bone and soft tissue))
Child and Teen Health

IRB Number

23-0259

ClinicalTrials.gov

NCT05634369

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.